Table 6 Relationship between length of non-steroideal anti-inflammatory drug consumption and breast cancer, according to tumor characteristics
Variable | Category | NSAID | No consumption | Consumption ≤5y | Consumption >5y | ||
|---|---|---|---|---|---|---|---|
Controls/cases (n) | Controls/cases (n) | OR (95 % CI) | Controls/cases (n) | OR (95 % CI) | |||
Clinical stage | 1–2 | NSAID (all) | 1171/695 | 484/281 | 0.85 (0.69–1.06) | 255/123 | 0.69 (0.52–0.92) |
Aspirin | 1808/1047 | 79/44 | 1.01 (0.65–1.58) | 23/8 | 0.74 (0.31–1.73) | ||
Acetic acid derivatives | 1754/1025 | 113/53 | 0.79 (0.53–1.17) | 43/21 | 0.73 (0.38–1.42) | ||
Propionic acid derivatives | 1351/770 | 380/234 | 0.93 (0.73–1.17) | 179/95 | 0.78 (0.57–1.08) | ||
NSAID others | 1862/1072 | 33/24 | 1.56 (0.82–2.95) | 15/3 | - | ||
3–4 | NSAID (all) | 1171/136 | 484/54 | 0.85 (0.57–1.27) | 255/14 | 0.46 (0.24–0.88) | |
Aspirin | 1808/192 | 79/11 | 1.61 (0.78–3.34) | 23/1 | - | ||
Acetic acid derivatives | 1754/190 | 113/12 | 1.08 (0.54–2.17) | 43/2 | - | ||
Propionic acid derivatives | 1351/147 | 380/45 | 0.91 (0.59–1.40) | 179/12 | 0.54 (0.27–1.09) | ||
NSAID others | 1862/201 | 33/3 | - | 15/0 | - | ||
Pathology | Ductal cancer | NSAID (all) | 1171/835 | 484/324 | 0.74 (0.60–0.91) | 255/130 | 0.60 (0.45–0.79) |
Aspirin | 1808/1225 | 79/56 | 1.09 (0.72–1.66) | 23/8 | 0.60 (0.26–1.41) | ||
Acetic acid derivatives | 1754/1204 | 113/64 | 0.78 (0.53–1.14) | 43/21 | 0.68 (0.36–1.30) | ||
Propionic acid derivatives | 1351/918 | 380/270 | 0.81 (0.65–1.02) | 179/101 | 0.68 (0.49–0.94) | ||
NSAID others | 1862/1259 | 33/28 | 1.42 (0.77–2.67) | 15/2 | |||
Non-ductal cancer | NSAID (all) | 1171/151 | 484/50 | 0.78 (0.53–1.15) | 255/33 | 0.90 (0.55–1.48) | |
Aspirin | 1808/228 | 79/5 | 0.59 (0.23–1.53) | 23/1 | - | ||
Acetic acid derivatives | 1754/219 | 113/11 | 0.92 (0.45–1.87) | 43/4 | - | ||
Propionic acid derivatives | 1351/166 | 380/40 | 0.79 (0.51–1.22) | 179/28 | 1.15 (0.67–1.96) | ||
NSAID others | 1862/232 | 33/1 | - | 15/1 | - | ||
Inmunohisto-chemistry | Hormone + | NSAID (all) | 1171/727 | 484/267 | 0.74 (0.60–0.92) | 256/123 | 0.69 (0.52–0.92) |
Aspirin | 1808/1069 | 79/38 | 0.85 (0.54–1.36) | 23/10 | 0.79 (0.36–1.75) | ||
Acetic acid derivatives | 1754/1044 | 113/50 | 0.69 (0.46–1.04) | 43/23 | 0.94 (0.51–1.75) | ||
Propionic acid derivatives | 1351/805 | 380/221 | 0.82 (0.65–1.04) | 179/91 | 0.76 (0.55–1.05) | ||
NSAID others | 1862/1089 | 33/25 | 1.62 (0.87–3.01) | 15/3 | - | ||
HER2 +/Hormone- | NSAID (all) | 1171/172 | 484/61 | 0.70 (0.48–1.01) | 255/22 | 0.49 (0.28–0.87) | |
Aspirin | 1808/244 | 79/10 | 0.89 (0.41–1.96) | 23/1 | - | ||
Acetic acid derivatives | 1754/238 | 113/16 | 1.02 (0.29–3.60) | 43/1 | - | ||
Propionic acid derivatives | 1351/188 | 380/47 | 0.66 (0.43–0.99) | 179/20 | 0.61 (0.33–1.12) | ||
NSAID others | 1862/251 | 33/4 | - | 15/0 | - | ||
Triple negative breast cancer | NSAID (all) | 1171/94 | 484/49 | 0.94 (0.60–1.48) | 255/14 | 0.60 (0.30–1.17) | |
Aspirin | 1808/148 | 79/9 | 1.74 (0.78–3.89) | 23/0 | - | ||
Acetic acid derivatives | 1754/144 | 113/8 | 0.85 (0.36–2.01) | 43/2 | - | ||
Propionic acid derivatives | 1351/103 | 380/42 | 1.04 (0.64–1.68) | 179/12 | 0.68 (0.32–1.43) | ||
NSAID others | 1862/154 | 33/2 | - | 15/1 | - | ||